Kroeger, N. Et Al. 2021. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. LEUKEMIA , vol.35, no.12 , 3551-3560.

Kroeger, N., Sbianchi, G., Sirait, T., Wolschke, C., Beelen, D., Passweg, J., ... Robin, M.(2021). Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. LEUKEMIA , vol.35, no.12, 3551-3560.

Kroeger, Nicolaus Et Al. "Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT," LEUKEMIA , vol.35, no.12, 3551-3560, 2021

Kroeger, Nicolaus Et Al. "Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT." LEUKEMIA , vol.35, no.12, pp.3551-3560, 2021

Kroeger, N. Et Al. (2021) . "Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT." LEUKEMIA , vol.35, no.12, pp.3551-3560.

@article{article, author={Nicolaus Kroeger Et Al. }, title={Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT}, journal={LEUKEMIA}, year=2021, pages={3551-3560} }